Headquartered in Edmonton, AB Fiscal year ends December NASDAQ: AUPH auriniapharma.com
Aurinia Pharmaceuticals is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. Its commercial product, LUPKYNIS (voclosporin), is the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia generates revenue primarily through U.S. net product sales of LUPKYNIS, supplemented by license, collaboration and royalty revenue from partnerships. The company is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which has entered clinical development in four potential autoimmune disease indications. Aurinia trades on NASDAQ under the ticker AUPH. Updated
Berkshire Hathaway has resumed acquiring shares of Warren Buffett's favorite media stock. Other insider buyers are focused on three biotech stocks.
Officers, beneficial owners, and other insiders have shelled out more than $10 million on each of these four biotech stocks in the past week.
The most notable insider purchases of stock in the past week were in biotech and energy companies, as well as a specialty retailer.
Aurinia Pharmaceuticals is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. Its commercial product, LUPKYNIS (voclosporin), is the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis.
The Wall Street consensus 12-month price target for AUPH is $17.86.
